Drug Free Depression Treatment Market: Current Analysis and Forecast (2023-2030)

Depression is a common and serious mood disorder that affects a person's feeling, thinking, and other daily activities. It can cause persistent feelings of sadness, hopelessness, and loss of interest in activities once a person enjoyed. Depression can interfere with their ability to function at work, school, or in daily life and can also lead to a variety of physical symptoms such as changes in appetite or sleep patterns, fatigue, and physical aches or pains. Drug-free depression treatment refers to approaches and therapies used to manage depression without the use of medication. People find relief from depression symptoms through alternative therapies such as acupuncture, massage therapy, herbal remedies, or relaxation techniques like progressive muscle relaxation or biofeedback which is leading to the growth of the market. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are leading drivers of drug free depression treatment globally.

The Drug Free Depression Treatment Market is expected to grow at a steady rate of around 10.1% owing to the rising cases of depression. For instance, according to the World Health Organization, an estimated 3.8% of the population experience depression, including 5% of adults -4% among men and 6% among women, and 5.7% of adults older than 60 years. Several factors, including a surge in the incidence of anxiety cases, increasing awareness regarding mental health, and increased investments in psychology departments are driving the market's growth during the forecast period. Apart from this, accelerated treatment efficiency with drug free depression treatment has resulted in effective treatment procedures which are also driving this market of drug free depression treatment at a steady rate.

Based on the treatment type, the market is segmented into cognitive behavioural therapy, transcranial magnetic stimulation, herbal remedies, and others. The cognitive behavioural therapy segment held the maximum share in the global market of drug free depression treatment in 2022 owing to the rising demand for drug free depression treatment. For instance, in April 2022, new data analyzed by the Royal College of Psychiatrists showed a record number of 1,961,096 annual appointments for those accessing cognitive behavioral therapy (CBT) across England for the year 2021. Cognitive behavioral therapy (CBT) is a psychotherapy approach that focuses on the connections between thoughts, feelings, and behaviors. It aims to help individuals identify and change negative thought patterns and behaviors contributing to their problems. It's often structured, goal-oriented, and involves practical strategies for managing symptoms and improving overall well-being. Thus, among the treatment type, the cognitive behavioural therapy segment held a significant market share in 2022.

Based on facility type, the market is categorized into hospitals, specialized clinics, and rehabilitation centers. The rehabilitation centers segment is expected to hold a significant share of the market in the forecast period owing to the rising cases of depression. For instance, according to a scientific brief released by the World Health Organization (WHO) in the year 2021, the global prevalence of anxiety and depression increased by a massive 25%. Rehabilitation centers are specialized facilities that provide structured programs and therapies to individuals recovering from various health conditions, including depression. These centers offer comprehensive care tailored to meet the unique needs of each individual. Thus, the rehabilitation centers category is expected to witness a higher CAGR amongst facility types during the forecast period.

For a better understanding of the market adoption of drug free depression treatment, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the rising awareness about the adverse effects of drugs, and the rising number of investments in introducing innovative drug free depression therapies. Government organizations are initiating mental health awareness programs for the sake of the growing rate of depression cases in the region. For instance, according to Statistics Canada's report in September 2023, the percentage of Canadians aged 15 years and older suffering from major depressive episodes, bipolar disorder, and generalized anxiety disorder has increased in the past 10 years. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include McLean Hospital; Great Oaks Recovery Center; Mayo Foundation for Medical Education and Research (MFMER); Fortis Healthcare; Cleveland Clinic; Craig Hospital; Select Medical Corporation; LHC Group, Inc.; Thomas Jefferson University Hospitals; NYU Langone Hospitals.